MA32998B1 - Chlorhydrate de n-{(1-s)-2-amino-1-[(3-fluorophényl) méthyl]éthyl}-5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophènecarboxamide cristallin - Google Patents

Chlorhydrate de n-{(1-s)-2-amino-1-[(3-fluorophényl) méthyl]éthyl}-5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophènecarboxamide cristallin

Info

Publication number
MA32998B1
MA32998B1 MA34058A MA34058A MA32998B1 MA 32998 B1 MA32998 B1 MA 32998B1 MA 34058 A MA34058 A MA 34058A MA 34058 A MA34058 A MA 34058A MA 32998 B1 MA32998 B1 MA 32998B1
Authority
MA
Morocco
Prior art keywords
chloro
methyl
pyrazol
fluorophenyl
crystalline
Prior art date
Application number
MA34058A
Other languages
Arabic (ar)
English (en)
Inventor
Pingyun Y Chen
Jeffrey Gaulding
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42395995&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32998(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of MA32998B1 publication Critical patent/MA32998B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'INVENTION PORTE SUR UN COMPOSÉ INHIBANT L'AKT AMÉLIORÉ, LE CHLORHYDRATE DE N-{(1-S)-2-AMINO-1-[(3-FLUOROPHÉNYL)MÉTHYL]ÉTHYL}-5-CHLORO-4- (4-CHLORO-1-METHYL-1H-PYRAZOL-5-YL)-2-THIOPHÈNECARBOXAMIDE CRISTALLIN.
MA34058A 2009-01-30 2010-01-28 Chlorhydrate de n-{(1-s)-2-amino-1-[(3-fluorophényl) méthyl]éthyl}-5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophènecarboxamide cristallin MA32998B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14849009P 2009-01-30 2009-01-30
PCT/US2010/022323 WO2010088331A1 (fr) 2009-01-30 2010-01-28 Chlorhydrate de n-{(1-s)-2-amino-1-[(3-fluorophényl)méthyl]éthyl}-5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophènecarboxamide cristallin

Publications (1)

Publication Number Publication Date
MA32998B1 true MA32998B1 (fr) 2012-01-02

Family

ID=42395995

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34058A MA32998B1 (fr) 2009-01-30 2010-01-28 Chlorhydrate de n-{(1-s)-2-amino-1-[(3-fluorophényl) méthyl]éthyl}-5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophènecarboxamide cristallin

Country Status (25)

Country Link
US (5) US8609711B2 (fr)
EP (2) EP4242206A1 (fr)
JP (4) JP2012516344A (fr)
KR (1) KR101420484B1 (fr)
CN (1) CN102405047B (fr)
AR (1) AR075153A1 (fr)
AU (1) AU2010208265B2 (fr)
BR (1) BRPI1006896B1 (fr)
CA (1) CA2750565C (fr)
CL (1) CL2011001830A1 (fr)
CO (1) CO6400189A2 (fr)
CR (1) CR20110422A (fr)
EA (1) EA018907B1 (fr)
IL (1) IL214023A (fr)
MA (1) MA32998B1 (fr)
MX (1) MX2011008073A (fr)
MY (1) MY161598A (fr)
NZ (1) NZ594064A (fr)
PE (1) PE20120003A1 (fr)
SG (1) SG172926A1 (fr)
TW (1) TWI503317B (fr)
UA (1) UA106740C2 (fr)
UY (1) UY32407A (fr)
WO (1) WO2010088331A1 (fr)
ZA (1) ZA201105033B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY161598A (en) 2009-01-30 2017-04-28 Glaxosmithkline Llc Crystalline n-{ (1s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl} -5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride
JP2013526578A (ja) * 2010-05-21 2013-06-24 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 組合せ
JP2013526613A (ja) * 2010-05-26 2013-06-24 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 組合せ
AU2012205601B2 (en) * 2011-01-11 2016-03-24 Novartis Ag Combination
EP2841053A1 (fr) * 2012-04-24 2015-03-04 Glaxosmithkline Intellectual Property (No. 2) Limited Méthode de traitement de dermatoses répondant aux stéroïdes
CN105473136A (zh) * 2013-04-18 2016-04-06 国家健康与医学研究院 用于在有此需要的受试者中抑制淋巴细胞增殖的方法和药物组合物
MX2016004267A (es) * 2013-10-01 2016-07-08 Novartis Ag Combinacion.
US20160235714A1 (en) * 2013-10-01 2016-08-18 Novartis Ag Enzalutamide in combination with afuresertib for the treatment of cancer
KR20160127754A (ko) * 2014-03-12 2016-11-04 노파르티스 아게 Btk 억제제 및 akt 억제제를 포함하는 조합물
PL3525774T3 (pl) 2016-10-11 2022-04-25 Duke University Leczenie lazofoksyfenem raka piersi er+
JP6515944B2 (ja) 2016-12-20 2019-05-22 株式会社デンソー 半導体装置およびその製造方法
WO2019199891A1 (fr) 2018-04-10 2019-10-17 Duke University Traitement du cancer du sein avec du lasofoxifène
US20210038578A1 (en) 2019-08-08 2021-02-11 Laekna Limited Method of treating cancer
US11915283B1 (en) 2019-08-13 2024-02-27 Splitcart Llc Cost sharing platform and system
US12067592B2 (en) 2019-08-13 2024-08-20 Splitcart Llc Co-purchasing system and method
GB202116903D0 (en) * 2021-11-18 2022-01-05 Sermonix Pharmaceuticals Inc Lasofoxifene treatment of aromatase-resistant er+ cancer
CN119013022A (zh) 2022-03-14 2024-11-22 来凯有限公司 癌症的组合治疗

Family Cites Families (142)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE758350A (fr) * 1969-12-30 1971-05-03 Pfizer Procede de fabrication des sels mono- et bi-metalliques alcalins de l'alpha-carboxybenzylpenicilline
US4432987A (en) * 1982-04-23 1984-02-21 Pfizer Inc. Crystalline benzenesulfonate salts of sultamicillin
CN1030415A (zh) * 1987-02-20 1989-01-18 山之内制药株式会社 饱和的杂环碳酰胺衍生物和它的制备方法
ES2005163A6 (es) 1987-04-14 1989-03-01 Lilly S A E Un procedimiento para la produccion de derivados de tiofen-2-carboxamida.
PT90001B (pt) 1988-03-16 1994-06-30 Zambeletti Spa L Processo para a preparacao de derivados heterociclicos de etilenodiamina
DE3810848A1 (de) 1988-03-30 1989-10-19 Boehringer Ingelheim Kg Neue 2,3,4-substituierte imidazole und 3,4,5-substituierte 1,2,4-triazole, ihre herstellung und verwendung
US4999059A (en) * 1989-08-11 1991-03-12 Bagno Robert G Universal solar concentrator panel
DE3927483A1 (de) 1989-08-19 1991-02-21 Boehringer Ingelheim Kg Neue substituierte heterocyclische fuenfringe, ihre herstellung und verwendung
US5258357A (en) * 1989-10-07 1993-11-02 Basf Aktiengesellschaft Carboxamides, their preparation and their use as herbicides
DE3933573A1 (de) * 1989-10-07 1991-04-18 Basf Ag Carbonsaeureamide, verfahren zu ihrer herstellung und ihre verwendung als herbizide
US6645969B1 (en) * 1991-05-10 2003-11-11 Aventis Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
US5559235A (en) 1991-10-29 1996-09-24 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
US5595872A (en) * 1992-03-06 1997-01-21 Bristol-Myers Squibb Company Nucleic acids encoding microsomal trigyceride transfer protein
DE4233198A1 (de) * 1992-10-02 1994-04-07 Bayer Ag Substituierte Thiophencarbonsäureamide
US5342947A (en) 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
JP3322878B2 (ja) * 1992-10-14 2002-09-09 メルク エンド カンパニー インコーポレーテッド フィブリノーゲンレセプターアンタゴニスト
CA2146019A1 (fr) * 1992-10-23 1994-05-11 Howard B. Broughton Ligands de sous-types de recepteurs dopaminergiques
KR100296810B1 (ko) * 1993-03-12 2001-10-24 로렌스 티. 마이젠헬더 결정성세프티오퍼유리산
DE69418045T2 (de) 1993-08-06 1999-10-07 Smithkline Beecham P.L.C., Brentford Amidderivate als 5ht1d rezeptor antagonisten
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5491237A (en) 1994-05-03 1996-02-13 Glaxo Wellcome Inc. Intermediates in pharmaceutical camptothecin preparation
US5668148A (en) * 1995-04-20 1997-09-16 Merck & Co., Inc. Alpha1a adrenergic receptor antagonists
JP3964478B2 (ja) * 1995-06-30 2007-08-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬
EP1304322A3 (fr) * 1995-08-22 2003-11-19 Japan Tobacco Inc. Composé d'acide carboxylique et son utilisation
US6001866A (en) 1995-10-05 1999-12-14 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
AU6966696A (en) * 1995-10-05 1997-04-28 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
US5972980A (en) * 1995-10-05 1999-10-26 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
AU6320998A (en) * 1997-02-21 1998-09-09 Bristol-Myers Squibb Company Benzoic acid derivatives and related compounds as antiarrhythmic agents
US5998336A (en) 1997-02-26 1999-12-07 The Board Of Trustees Of The Leland Stanford Junior University Ceramic/metal and A15/metal superconducting composite materials exploiting the superconducting proximity effect and method of making the same
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
DE19744026A1 (de) 1997-10-06 1999-04-08 Hoechst Marion Roussel De Gmbh Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
AU751139B2 (en) * 1997-10-13 2002-08-08 Astellas Pharma Inc. Amide derivative
HUP0301166A2 (en) * 1997-12-12 2003-08-28 Euro Celtique Sa 3-substituted adenines via2-thioxanthines
US6232320B1 (en) * 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
AUPP433398A0 (en) * 1998-06-25 1998-07-16 Australian National University, The Compounds and processes
US6192967B1 (en) * 1998-10-19 2001-02-27 Sunny En Liung Huang Collapsible auto shade
US6130333A (en) * 1998-11-27 2000-10-10 Monsanto Company Bicyclic imidazolyl derivatives as phosphodiesterase inhibitors, pharmaceutical compositions and method of use
DE19904397A1 (de) 1999-02-04 2000-08-10 Bayer Ag Verwendung von Pyrazol-Carbonsäureamiden
DE19904396A1 (de) 1999-02-04 2000-08-10 Bayer Ag Substituierte Pyrazolbenzylamin-Derivate
JP2000256358A (ja) 1999-03-10 2000-09-19 Yamanouchi Pharmaceut Co Ltd ピラゾール誘導体
HK1046279A1 (zh) * 1999-04-13 2003-01-03 Abbott Gmbh & Co. Kg 整合素受體配體
JP2003500376A (ja) * 1999-05-24 2003-01-07 シーオーアール セラピューティクス インコーポレイテッド Ｘａ因子の阻害剤
JP2003500386A (ja) * 1999-05-24 2003-01-07 シーオーアール セラピューティクス インコーポレイテッド Ｘａ因子阻害剤
GEP20053476B (en) * 1999-08-12 2005-03-25 Upjohn Co 3(5)-Amino-Pyrazole Derivatives, Process for Their Preparation and Their Use as Antitumor Agents
JP2001247569A (ja) 1999-08-12 2001-09-11 Japan Tobacco Inc ピロリジン誘導体又はピペリジン誘導体及びその医薬用途
US6632815B2 (en) * 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
DE19962924A1 (de) * 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
US6770666B2 (en) * 1999-12-27 2004-08-03 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
CA2363274A1 (fr) * 1999-12-27 2001-07-05 Japan Tobacco Inc. Composes a noyaux fusionnes et leurs utilisations comme medicaments contre l'hepatite c
AU2001250783A1 (en) * 2000-02-29 2001-09-12 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
GB0011098D0 (en) * 2000-05-08 2000-06-28 Black James Foundation Pharmaceutical compositions comprising protpn pump inhibitors and gastrin/cholecystokinin receptor ligands
PT1282418E (pt) * 2000-05-19 2005-10-31 Applied Research Systems Utilizacao de derivados pirazolo para o tratamento da infertilidade
US6589195B1 (en) * 2000-05-26 2003-07-08 Orthomerica Products, Inc. Modular adjustable prophylactic hip orthosis and adduction/abduction joint
AU2001268711A1 (en) * 2000-06-23 2002-01-08 Bristol-Myers Squibb Pharma Company Heteroaryl-phenyl substituted factor xa inhibitors
US6624039B1 (en) * 2000-07-13 2003-09-23 Lucent Technologies Inc. Alignment mark having a protective oxide layer for use with shallow trench isolation
AU2001277143A1 (en) 2000-07-24 2002-02-05 Davide Riccardo Grassetti Inhibition of mutagenic effects of carcinogens
JO2654B1 (en) * 2000-09-04 2012-06-17 شركة جانسين فارماسوتيكا ان. في Multiple aryl caroxa amides are useful as lipid - lowering agents
DE10061876A1 (de) * 2000-12-12 2002-06-20 Aventis Pharma Gmbh Arylierte Furan- und Thiophencarbonsäureamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
WO2002064136A2 (fr) * 2001-01-26 2002-08-22 Chugai Seiyaku Kabushiki Kaisha Inhibiteurs de malonyl-coa decarboxylase utiles en tant que modulateurs metaboliques
DE60227794D1 (de) * 2001-04-26 2008-09-04 Eisai R&D Man Co Ltd Stickstoffhaltige verbindung mit kondensiertem ring und pyrazolylgruppe als substituent und medizinische zusammensetzung davon
CA2445568A1 (fr) * 2001-04-27 2002-11-07 Vertex Pharmaceuticals Incorporated Derives triazole inhibiteurs des kinases et leurs utilisations
CA2456192A1 (fr) * 2001-08-03 2003-02-13 Qing Tang Inhibiteurs de kinase derives du pyrazole et leurs utilisations
DE60238620D1 (de) * 2001-08-03 2011-01-27 Vertex Pharma Von pyrazol abgeleitete kinaseinhibitoren und deren verwendung
EP1442038A4 (fr) * 2001-09-26 2005-01-05 Merck & Co Inc Formes cristallines d'antibiotiques a base de carbapeneme et procedes de preparation
US20040198799A1 (en) * 2001-09-27 2004-10-07 Brondyk William H. Methods of increasing endogenous testosterone levels
US6794252B2 (en) * 2001-09-28 2004-09-21 Texas Instruments Incorporated Method and system for forming dual work function gate electrodes in a semiconductor device
US6897208B2 (en) * 2001-10-26 2005-05-24 Aventis Pharmaceuticals Inc. Benzimidazoles
WO2003039529A1 (fr) * 2001-11-07 2003-05-15 4Sc A.G. Agents antibacteriens selectifs
TW200306819A (en) * 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
KR20040084896A (ko) * 2002-02-06 2004-10-06 버텍스 파마슈티칼스 인코포레이티드 Ｇｓｋ-3의 억제제로서 유용한 헤테로아릴 화합물
US7335779B2 (en) * 2002-03-08 2008-02-26 Quonova, Llc Modulation of pathogenicity
GB0206861D0 (en) * 2002-03-22 2002-05-01 Glaxo Group Ltd Medicaments
GB0206860D0 (en) * 2002-03-22 2002-05-01 Glaxo Group Ltd Compounds
US20050154202A1 (en) 2002-04-05 2005-07-14 Hagmann William K. Substituted aryl amides
GB0216224D0 (en) * 2002-07-12 2002-08-21 Glaxo Group Ltd Compounds
BR0313160A (pt) * 2002-08-08 2005-07-12 Smithkline Beecham Corp Composto, composição farmacêutica, métodos para tratar uma condição e um neoplasmo suscetìvel em um animal em um animal, processo para preparar um composto e uso de um composto
AU2003268064A1 (en) * 2002-08-09 2004-02-25 Astrazeneca Ab Oxadiazoles as modulators of metabotropic glutamate receptor-5
AU2003265395A1 (en) * 2002-08-14 2004-03-03 Ppd Discovery, Inc. Prenylation inhibitors and methods of their synthesis and use
US6649638B1 (en) 2002-08-14 2003-11-18 Ppd Discovery, Inc. Prenylation inhibitors and methods of their synthesis and use
ATE477251T1 (de) * 2002-08-23 2010-08-15 Novartis Vaccines & Diagnostic Pyrrolverbindungen als glykogen synthase kinase 3 inhibitoren
EP1594846A1 (fr) 2003-02-10 2005-11-16 Bayer HealthCare AG Derives de bis(hetero)aryle carboxamide destines a etre utilises en tant qu'antagonistes de la pg12
WO2004072018A1 (fr) * 2003-02-12 2004-08-26 Takeda Pharmaceutical Company Limited Derive d'amine
US7223788B2 (en) * 2003-02-14 2007-05-29 Sanofi-Aventis Deutschland Gmbh Substituted N-aryl heterocycles, process for their preparation and their use as medicaments
WO2004076418A1 (fr) * 2003-02-28 2004-09-10 Galderma Research & Development, S.N.C. Ligands modulant des recepteurs du type lxr
US7517887B2 (en) * 2003-04-09 2009-04-14 General Atomics Reversible inhibitors of S-adenosyl-L-homocysteine hydrolase and uses thereof
CA2523232A1 (fr) * 2003-04-21 2004-11-04 Elan Pharmaceuticals, Inc. Benzamide 2-hydroxy-3-diaminoalcanes
JP4638423B2 (ja) * 2003-06-20 2011-02-23 ガルデルマ・リサーチ・アンド・デヴェロップメント ＰＰＡＲγタイプ受容体を調節する新規化合物および化粧品組成物または医薬品組成物へのその使用
FR2857666B1 (fr) 2003-07-15 2005-08-26 Oreal Composition tinctoriale comprenant a titre de coupleur un derive du furane et nouveaux derives du furane
HRP20110180T1 (hr) * 2003-07-23 2011-04-30 Synta Pharmaceuticals Corporation Spojevi za upotrebu kod upala i upotrebe vezane uz imunitet
CA2536470A1 (fr) * 2003-08-15 2005-02-24 Vertex Pharmaceuticals Incorporated Compositions de pyrrole convenant comme inhibiteurs de c-met
JP2007507549A (ja) * 2003-10-06 2007-03-29 グラクソ　グループ　リミテッド キナーゼ阻害剤としての１，６，７−三置換アザベンゾイミダゾールの調製
JP2007507547A (ja) * 2003-10-06 2007-03-29 グラクソ　グループ　リミテッド キナーゼ阻害剤としての１，７−二置換アザベンゾイミダゾールの調製
CA2545711A1 (fr) * 2003-11-13 2005-06-02 Ambit Biosciences Corporation Derives d'uree en tant que modulateurs de la kinase
EP1684694A2 (fr) * 2003-11-21 2006-08-02 Array Biopharma, Inc. Inhibiteurs de la proteine kinase akt
US20050145202A1 (en) * 2004-01-05 2005-07-07 James Bonner Rigid dog leash
WO2005077435A1 (fr) * 2004-01-19 2005-08-25 Atul Kumar Systeme permettant de distendre des cavites corporelles tissulaires par irrigation a ecoulement continu
WO2005081954A2 (fr) * 2004-02-25 2005-09-09 Wyeth Inhibiteurs de la proteine tyrosine phosphatase 1b
ES2551293T3 (es) * 2004-03-24 2015-11-17 Abbvie Inc. Inhibidores de quinasas de pirazol tricíclicos
RU2006138036A (ru) 2004-03-30 2008-05-10 Чирон Корпорейшн (Us) Производные замещенного тиофена в качестве противораковых средств
CA2559866A1 (fr) * 2004-03-31 2005-10-20 Exelixis, Inc. Modulateurs de kinases de lymphomes anaplasiques (alk) et methodes d'utilisation
JP2005336172A (ja) 2004-04-26 2005-12-08 Japan Tobacco Inc 腎虚血再灌流障害治療又は予防薬
MXPA06013924A (es) * 2004-05-29 2007-07-18 7Tm Pharma As Acidos tiazolaceticos sustituidos como ligandos crth2.
US20060135773A1 (en) * 2004-06-17 2006-06-22 Semple Joseph E Trisubstituted nitrogen modulators of tyrosine phosphatases
US7671077B2 (en) * 2004-07-19 2010-03-02 Leu-Fen Hou Lin Neuroprotective small organic molecules, compositions and uses related thereto
JP2006066488A (ja) * 2004-08-25 2006-03-09 Mitsubishi Electric Corp 半導体受光素子およびその製造方法
US7365385B2 (en) * 2004-08-30 2008-04-29 Micron Technology, Inc. DRAM layout with vertical FETs and method of formation
US20060043513A1 (en) * 2004-09-02 2006-03-02 Deok-Hoon Kim Method of making camera module in wafer level
TW200616969A (en) * 2004-09-17 2006-06-01 Tanabe Seiyaku Co Imidazole compound
US20060062453A1 (en) * 2004-09-23 2006-03-23 Sharp Laboratories Of America, Inc. Color highlighting document image processing
WO2006040649A1 (fr) * 2004-10-13 2006-04-20 Pharmacia & Upjohn Company Llc Formes cristallines de 3-[5-chloro-4-[(2,4-difluorobenzyl) oxy]-6-oxopyrimidin-1(6h)-yl]-n-(2-hydroxyethyl)-4-methylbenzamide
DE102004051277A1 (de) 2004-10-21 2006-04-27 Merck Patent Gmbh Heterocyclische Carbonylverbindungen
DE102004054666A1 (de) 2004-11-12 2006-05-18 Bayer Cropscience Gmbh Substituierte Pyrazol-3-carboxamide, Verfahren zur Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren
EP1819709B1 (fr) 2004-11-30 2009-02-11 Neurosearch A/S Nouveaux derives aryliques diazabicycliques utilises en tant que ligands cholinergiques
JP2006232707A (ja) 2005-02-23 2006-09-07 Japan Tobacco Inc 癌転移抑制剤
CA2605603A1 (fr) 2005-04-22 2006-11-02 Kalypsys, Inc. Inhibiteurs ortho-terphenyle de kinase p38 et procedes de traitement des troubles inflammatoires
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
WO2006136823A1 (fr) 2005-06-21 2006-12-28 Astex Therapeutics Limited Amine contenant des heterocycliques comme inhibiteurs des kinases b
US20060288588A1 (en) 2005-06-22 2006-12-28 Frank Morabito Garden tool
CN101223161A (zh) 2005-06-24 2008-07-16 健亚生物科技公司 治疗病毒感染的杂芳基衍生物
JP5237799B2 (ja) 2005-06-27 2013-07-17 エグゼリクシス パテント カンパニー エルエルシー ピラゾールベースのｌｘｒモジュレーター
CN100494167C (zh) 2005-08-02 2009-06-03 天津大学 抗乙肝病毒的叔胺氧化物及制备方法和制备药物的应用
GB0518237D0 (en) * 2005-09-07 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
WO2007052843A1 (fr) 2005-11-04 2007-05-10 Takeda Pharmaceutical Company Limited Compose amide heterocyclique et son utilisation
US7838676B2 (en) * 2005-11-21 2010-11-23 Amgen Inc. Beta-secretase modulators and methods of use
JP2009519966A (ja) * 2005-12-14 2009-05-21 ブリストル−マイヤーズ スクイブ カンパニー セリンプロテアーゼ阻害剤として有用な６員ヘテロ環
EP1968568A4 (fr) 2005-12-22 2011-04-13 Glaxosmithkline Llc INHIBITEURS D'ACTIVITE Akt
MX2008008320A (es) * 2005-12-23 2008-09-03 Smithkline Beecham Corp Inhibidores de azaindol de aurora cinasas.
EP2465850B1 (fr) * 2006-02-28 2016-11-23 Dart Neuroscience (Cayman) Ltd Composés thérapeutiques
JP2007277230A (ja) 2006-03-15 2007-10-25 Tanabe Seiyaku Co Ltd 医薬組成物
EP1840114A1 (fr) * 2006-03-30 2007-10-03 LTB4 Sweden AB Leukotriène B4 crystallisé
WO2007122686A1 (fr) * 2006-04-14 2007-11-01 Eisai R & D Management Co., Ltd. Composes benzimidazole
US20080027044A1 (en) * 2006-06-13 2008-01-31 Kim Lewis Prodrug antibiotic screens
US8357695B2 (en) * 2006-10-13 2013-01-22 Basf Se Hydrates of 2-chloro-5-[3,6-dihydro-3-methyl-2,6-dioxo-4-(trifluoromethyl)-1-(2H)-pyrimidinyl]-4-fluoro-N-[[methyl(1-methylethyl)amino]sulfonyl]benzamide
WO2008057775A2 (fr) * 2006-10-27 2008-05-15 Bristol-Myers Squibb Company Composés d'amide hétérocyclique utiles comme inhibiteurs de kinase
KR20090086115A (ko) * 2006-12-22 2009-08-10 엔싸이시브 파마슈티칼즈 인코퍼레이티드 Ｃ３ａ 수용체의 조정제 및 이의 사용 방법
WO2008091532A1 (fr) * 2007-01-19 2008-07-31 Panacos Pharmaceuticals, Inc. Sels de l'acide 3-o-(3',3'-diméthylsuccinyl)bétulinique et leurs formes à l'état solide
UY30892A1 (es) * 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
ES2543325T3 (es) 2007-02-07 2015-08-18 Glaxosmithkline Llc Inhibidores de la actividad de Akt
WO2008121685A1 (fr) 2007-03-28 2008-10-09 Smithkline Beecham Corporation Procédés d'utilisation pour inhibiteurs d'activité akt
JP2010522770A (ja) 2007-03-29 2010-07-08 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ａｋｔ活性の阻害物質
MY161598A (en) 2009-01-30 2017-04-28 Glaxosmithkline Llc Crystalline n-{ (1s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl} -5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride
US8977217B1 (en) 2013-02-20 2015-03-10 Triquint Semiconductor, Inc. Switching device with negative bias circuit

Also Published As

Publication number Publication date
CL2011001830A1 (es) 2012-04-09
PE20120003A1 (es) 2012-02-12
EP4242206A1 (fr) 2023-09-13
EP2400964A4 (fr) 2012-08-01
MY161598A (en) 2017-04-28
AU2010208265B2 (en) 2012-12-06
UA106740C2 (uk) 2014-10-10
CA2750565A1 (fr) 2010-08-05
ZA201105033B (en) 2012-03-28
KR20110117127A (ko) 2011-10-26
SG172926A1 (en) 2011-08-29
JP6924794B2 (ja) 2021-08-25
WO2010088331A1 (fr) 2010-08-05
TWI503317B (zh) 2015-10-11
JP2012516344A (ja) 2012-07-19
AR075153A1 (es) 2011-03-16
US20100197754A1 (en) 2010-08-05
MX2011008073A (es) 2011-11-18
CR20110422A (es) 2011-09-22
NZ594064A (en) 2012-08-31
US20140073679A1 (en) 2014-03-13
JP2017061559A (ja) 2017-03-30
JP6328590B2 (ja) 2018-05-23
US20150045405A1 (en) 2015-02-12
CA2750565C (fr) 2015-10-20
CN102405047B (zh) 2014-07-09
IL214023A (en) 2014-08-31
US8609711B2 (en) 2013-12-17
AU2010208265A1 (en) 2011-08-04
CO6400189A2 (es) 2012-03-15
IL214023A0 (en) 2011-08-31
EA201101144A1 (ru) 2011-12-30
BRPI1006896B1 (pt) 2022-05-24
US20110288142A1 (en) 2011-11-24
CN102405047A (zh) 2012-04-04
TW201038564A (en) 2010-11-01
JP2019135237A (ja) 2019-08-15
BRPI1006896A2 (pt) 2020-08-18
JP2015212269A (ja) 2015-11-26
EA018907B1 (ru) 2013-11-29
KR101420484B1 (ko) 2014-07-28
UY32407A (es) 2010-07-30
EP2400964A1 (fr) 2012-01-04
US20150353531A1 (en) 2015-12-10

Similar Documents

Publication Publication Date Title
MA32998B1 (fr) Chlorhydrate de n-{(1-s)-2-amino-1-[(3-fluorophényl) méthyl]éthyl}-5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophènecarboxamide cristallin
IN2012DN00913A (fr)
MX2010005889A (es) Derivados de tiofeno como agonistas de s1p1/edg1.
BRPI1008021A2 (pt) Método para fabricação de 2,6-dioxabiciclo-(3.3.0)-octano-4,8-diona
UA101409C2 (ru) Применение дитиинтетракарбоксимидов для борьбы с фитопатогенными грибами
UA107791C2 (en) Pesticidal compositions
MX2011009369A (es) 2-mercaptoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
IT1395588B1 (it) "cilindro monolucido coibentato"
PH12015502546B1 (en) 3-(4-isobutyl-2-methylphenyl) propanal as perfume ingredient
PL2131829T3 (pl) Agoniści PPAR-gamma do indukcji ekspresji kationowych peptydów przeciwbakteryjnych jako immunoochronne stymulatory
CL2011003009A1 (es) Proceso de preparacion de compuestos derivados de 4-fenil-3,5-(tio)piranodionas; compuesto intermediario; y preparacion de dicho intermediario.
MX2011008825A (es) 3-aminoisoxazolopiridinas sustituidas como moduladores de kcnq2/3.
MX2011008662A (es) 2-mercapto-3-aminopiridinas sustituidas como moduladores de kcnq2/3.
MX2011009338A (es) 3-amino-2-mercaptoquinolinas sustituidas como moduladores de kcnq2/3.
EP2537839A4 (fr) Composé dérivé de b-dihydrofurane, procédé pour produire un composé dérivé de b-dihydrofurane ou un composé dérivé de b-tétrahydrofurane, composé de b-glycoside, procédé pour produire un composé de b-glycoside, et procédé pour produire le 4'-éthynyl-d4t et des composés analogues de celui-ci
BR112012025490A2 (pt) ''método para produção de 1,5 oebtanodiamina''
UA108126C2 (uk) Спосіб отримання співполімеру натрійкарбоксиметилцелюлози й госиполу
IT1405996B1 (it) Procedimento per la preparazione di 2,5-diaminotoluolo
SG163478A1 (en) Polymer stabilizer
IN2012DN02000A (fr)
PH12012501244A1 (en) Polymer composition and molded articles shaped of the same
PL1865766T3 (pl) Gniazda dla niosek
IT1392158B1 (it) Procedimento per la preparazione di additivi per lubrificanti, contenenti cerio
PH12012501247A1 (en) Polymer composition and molded articles shaped of the same
IN2012DN00346A (fr)